CLINICAL_TRIALS
trial_result
· 2016-03-23
Clinical Trial Update: Sprifermin (AS902330) in Cartilage Injury Repair (CIR) [Phase 2]
Summary
A Phase 2 trial of sprifermin (AS902330) for isolated knee cartilage injury was terminated, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Isolated Cartilage Injury of the Knee | Phase 2 | Status: TERMINATED | Results posted: 2016-03-23